SWNM ‘26
The Light Medical team recently attended the South West Nuclear Medicine Meeting (SWNM ‘26), held at Exeter Science Park. The event brought together nuclear medicine professionals from across the South West and beyond, including clinicians, medical physicists, radiographers, radiopharmacists and industry partners.
For Light Medical, attending regional and national nuclear medicine events is an important way to stay closely connected with the professionals and departments we support across the UK. The SWNMM provides an excellent opportunity to engage directly with the nuclear medicine community, share knowledge, and discuss the evolving needs of clinical services.
Supporting the UK Nuclear Medicine Community
Light Medical works with hospitals and healthcare providers across the UK to supply and support nuclear medicine equipment, radiation shielding solutions, and specialist medical equipment. Events such as the South West Nuclear Medicine Meeting allow us to better understand the practical challenges faced by departments and explore how innovative solutions can improve workflow, safety, and efficiency.
During the meeting, our team had valuable conversations with nuclear medicine professionals about:
Radiation shielding and safety in clinical environments
Equipment reliability and service support
Workflow optimisation in nuclear medicine departments
Future developments in nuclear medicine technology
These discussions are essential in helping Light Medical continue to deliver solutions that meet the real-world needs of nuclear medicine departments.
Collaboration and Innovation in Nuclear Medicine
The South West Nuclear Medicine Meeting is well known for bringing together professionals from across multiple disciplines within nuclear medicine. The programme included expert presentations, research discussions, and networking opportunities that highlighted the importance of collaboration in advancing nuclear medicine services.
Industry exhibitions also play a key role in the meeting, giving suppliers and technology providers the opportunity to demonstrate products and services that support modern nuclear medicine practice. For Light Medical, it was a pleasure to meet both new and familiar faces and discuss how industry partnerships can help support safe and effective patient care.
Looking Ahead
At Light Medical, we are committed to supporting the continued development of nuclear medicine services across the UK. Attending events such as the South West Nuclear Medicine Meeting allows us to stay informed about the latest innovations, strengthen relationships within the community, and ensure that our products and services continue to meet the highest standards of quality and reliability.
We would like to thank the organisers and hosts for delivering such a well-organised and engaging event. We look forward to attending future meetings and continuing to work with nuclear medicine professionals to support the advancement of patient care.
About Light Medical
Light Medical supplies and supports specialist equipment for nuclear medicine departments across the UK, including radiation shielding, clinical equipment and technical solutions designed to improve safety, efficiency and reliability in healthcare environments. Learn more at www.lightmedical.co.uk.
Useful links
South West Nuclear Medicine Meeting
Light Medical 2026 conference listur story online can make all the difference.
Sealed source order deadlines 2026
In partnership with Epsilon Radioactive Sources and RadQual Global Sources we are planning to a do a monthly consolidated sealed source order. This will include all the sources from both catalogues - Co57 flood sources, PET/CT sources (GE Healthcare, Siemens and Philips) pen point marker sources, siemens AQC sources spot marker sources and dose calibrator sources. This will also include the collection and return of old sources. We also can do ad hoc collections, get in touch for details.
30th January (RadQual)
27th February (ERS)
31st March (RadQual)
30th April (ERS)
29th May (RadQual)
30th June (ERS)
31st July (RadQual)
31st August (ERS)
30th September (RadQual)
31st October (ERS)
30th November (RadQual)
23rd December (ERS)
Useful and related links
UKRG LEEDS ‘26
UK Radiopharmacy Group 2026
Light Medical attended the meeting in Leeds and had a great day catching up with the community. It was great to see so many familiar faces and connect with everyone in person.
There were some particularly interesting discussions around people’s plans for molecular therapy and the ONR’s views on the use of polymer pots, and we also shared an information piece on this topic.
We’re already looking ahead to 2026 and are excited to see everyone again at other conferences throughout the year (Where to find us). We also had in-depth conversations about all of our suppliers, including Raditech, Nuclear Shields, ERS, RadQual, and Isotopia.
Where to find us
Conferences and Events 2026
We will be attending a wide range of national and international conferences throughout 2026, spanning all key areas of our product portfolio and scientific interests. These events provide valuable opportunities to connect with clinical and research partners, share expertise, and stay at the forefront of developments across nuclear medicine, radiopharmacy, oncology, and imaging.
Our planned attendance includes the following events:
UKRG Annual Workshop | Leeds | 5th February 2026
South West Nuclear Medicine Meeting | Exeter | 11th March 2026
EAU26 | London | 13th–16th March 2026
BNMS Spring Meeting | Manchester | 20th–22th April 2026 | Stand No. 21
SNMMI Annual Meeting | Los Angeles | 30th May - 2nd June 2026
IRPA / SRP 2026 | Liverpool | 1st–5th June 2026 | Stand No. 72
UKIO 2026 | Liverpool | 8th–10th June 2026
UK PET Chemistry Meeting | Oxford | 16th September 2026
BNMS Autumn Meeting | Swansea | 25th September 2026
EANM 2026 | Vienna | 17th–21st October 2026
We look forward to engaging with colleagues across the community at these events and will share updates throughout the year. Shoudl you wish to meet us at one of these event contact us here and we can arrange a tine that suits you.
Suppliers we will be representing:
Raditech, Nuclear Shields, ERS, RadQual, and Isotopia.
Useful pages:
Understanding TYPE-A & assumption of compliance
Understanding Type A Packaging Compliance: Why Manufacturer-Supplied Lead Pots Cannot Be Assumed Compliant
Recent clarification from the Office for Nuclear Regulation (ONR) has highlighted an important and often misunderstood issue in the transport of radiopharmaceuticals: Type A package approval applies to a defined package and its approved contents, not to substitute containers used outside that approval.
This has particular relevance for departments using manufacturer-supplied polymer lead pots within Type A transport cases such as the TecCase or ViCad systems.
What Does a Type A Certificate Actually Cover?
A Type A certificate does not approve a transport case in isolation. Instead, it approves a complete package design, which includes:
The outer transport case
The internal shielded containers
The way shielding and containment requirements are achieved
In the case of the TecCase and ViCad systems, shielding and containment are provided by the stainless-steel internal containers, not by the outer case itself.
These approved containers are:
Designed to a controlled drawing set
Manufactured to known tolerances
Assessed for shielding and containment
Subject to quality assurance and periodic inspection
This design control is what allows compliance with transport regulations to be demonstrated.
Why Manufacturer-Supplied polymer Lead Pots Are Different
Manufacturer-supplied polymer lead pots are typically licensed for single use and supplied as part of a disposable transport system. When these containers are reused or incorporated into a different transport package, several compliance challenges arise.
Unlike approved stainless steel containers:
There is no master drawing set available
Manufacturing tolerances are unknown
Material properties and fatigue life are undocumented
Replacement parts and service criteria are undefined
Because of this, it is not possible to independently verify that a specific polymer lead pot continues to meet shielding and containment requirements over repeated use.
Key Compliance Risks Identified
To demonstrate compliance when using alternative containers, a consignor would need to assess and document, at a minimum:
Whether each container matches a defined and approved drawing
The specification, lifespan, and replacement interval of the integrated O-ring
Individual marking and traceability of each container
The properties of the plastic materials used, including brittleness and ageing
Whether additional crash protection is required to meet the 9-metre free-drop test
Whether repeated reuse could fatigue critical closure components
These factors are outside the control of most consignors and cannot be assumed based on previous use.
Design Changes and Regulatory Expectations
Transport regulations do allow a consignor to impose design changes on a Type A package. However, this is only permitted where suitable documentary evidence demonstrates that the change does not adversely affect compliance.
This requirement is set out in regulatory guidance (for example, NS-INSP-GD-075, Section 3.5).
Crucially, the burden of proof lies with the consignor. Any organisation choosing to use non-approved containers must be able to present a full compliance case to regulators, including physical testing where necessary.
Routes to Compliance
There are valid pathways available to demonstrate compliance:
Use the Type A package exactly as prescribed
This involves using the approved internal containers specified in the certificate, without substitution.Adopt a hybrid or modified design
This requires purchasing an approved transport case and conducting a full assessment of any design changes, including testing and documentation to demonstrate ongoing compliance.
Both approaches are acceptable, provided the necessary assessment, evidence, and regulatory engagement are in place.
Why This Matters
While the issue may appear technical, its implications are significant. Using containers outside their approved design scope can:
Invalidate Type A approval
Create regulatory non-compliance
Shift legal responsibility to the consignor
Introduce avoidable operational and safety risk
ONR’s position reinforces the principle that compliance cannot be assumed based on historical practice or convenience.
Final Thoughts
Radiopharmaceutical transport relies on clearly defined, demonstrably compliant systems. Where containers are licensed for single use, they cannot automatically be reused or redistributed within a Type A package without a documented compliance case.
As regulatory scrutiny increases, understanding the boundaries of Type A approval and the responsibility of the consignor is essential to maintaining safe, lawful, and reliable nuclear medicine services.
Terbium-161: A New Frontier in Targeted Radionuclide Therapy
Introduction
Recent advances in nuclear medicine are shining a spotlight on a promising new player: Terbium‑161 (¹⁶¹Tb). Long used radionuclides continue to form the backbone of targeted therapy, yet ¹⁶¹Tb brings a unique combination of physical properties — particularly the emission of short-ranged conversion and Auger electrons alongside traditional beta and gamma radiation — that might significantly enhance the effectiveness of treating microscopic disease and small metastases that often evade detection. Isotopia+2Journal of Nuclear Medicine+2
Where conventional radionuclides sometimes falter in eradicating minimal residual disease or tiny clusters of cancer cells, ¹⁶¹Tb may open the door to improved outcomes thanks to higher-density, localized radiation.
Why Terbium-161 Stands Out
• Radiobiological Advantages
Compared with the widely used Lutetium‑177 (¹⁷⁷Lu), ¹⁶¹Tb shares a similar half-life and decay scheme (beta emissions, gamma emissions suitable for imaging), making it relatively straightforward to integrate into existing radiopharmaceutical designs. PMC+2SpringerLink+2
However, the real distinction lies in the additional conversion and Auger electrons emitted by ¹⁶¹Tb after beta decay. These electrons have a very short range (on the order of 0.5–30 µm), allowing highly localized deposition of energy — ideal for destroying single tumor cells or small micrometastases while sparing surrounding healthy tissue. Isotopia+2Journal of Nuclear Medicine+2
Dosimetric comparisons show that for small volumes (10–100 µm), ¹⁶¹Tb can deliver 2–3 times higher energy transfer than ¹⁷⁷Lu, potentially translating into greater antitumour efficacy where small cell clusters or single-cell disease are involved. Isotopia+2Journal of Nuclear Medicine+2
• Versatile “Theranostic” Potential
Because ¹⁶¹Tb emits gamma rays as well as beta and Auger electrons, it can — in principle — be used for both therapy and imaging (SPECT), similar to existing theranostic pairings. PMC+2Frontiers+2
In practice, this dual role could simplify treatment workflows: the same molecular targeting agent (e.g. a peptide or ligand) labeled with ¹⁶¹Tb might first be used to image tumour distribution and dosimetry, then to deliver therapeutic radiation — enhancing personalization of radionuclide therapy. Frontiers+2SpringerLink+2
• Broad Applications — From Solid Tumours to Hematologic Malignancies
Initial research and clinical application have focused heavily on solid tumours — for instance, neuroendocrine tumours and prostate cancer — but the scope is expanding. Recent preclinical studies show that ¹⁶¹Tb-based radioimmunotherapy may also be effective against CD30-positive T-cell lymphomas, opening the door toward hematologic cancer applications. Journal of Nuclear Medicine+1
Moreover, because of its efficacy against small-volume disease — including circulating tumour cells and micrometastases — ¹⁶¹Tb may play a critical role in treating minimal residual disease, reducing relapse risk after standard therapies. Journal of Nuclear Medicine+2Nuclear Medicine Therapy+2
Progress & Challenges
Promising Clinical Data
One of the most significant developments occurred in 2025 with the first-in-human use of ¹⁶¹Tb-labeled radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC) — namely ¹⁶¹Tb-PSMA-I&T therapy. In a phase I/II clinical trial, doses up to 7.4 GBq were administered and the treatment was well tolerated, with only a minority of patients experiencing grade 3–4 adverse events. UroToday+2PubMed+2
Early efficacy signals have also been encouraging: a substantial proportion of patients experienced major declines in prostate-specific antigen (PSA) levels — a biomarker of disease burden — suggesting that ¹⁶¹Tb therapy can effectively reduce tumour load. UroToday+2UroToday+2
Preclinical data further supports superior potency of ¹⁶¹Tb over ¹⁷⁷Lu: in vitro studies reported multiple-fold stronger reduction in tumour cell viability with ¹⁶¹Tb-labeled compounds. Journal of Nuclear Medicine+2PMC+2
Manufacturing and Practical Challenges
Despite the promise, there remain non-trivial hurdles before ¹⁶¹Tb can become a mainstream therapeutic radionuclide. The main challenge lies in production at sufficient scale — neutron irradiation of highly enriched ^160Gd targets currently seems the most viable route, but achieving large-scale yields with consistent purity and specific activity is technically demanding. Isotopia+2National Isotope Development Center+2
Moreover, low-energy gamma emissions (e.g. ~49 keV, ~75 keV) pose challenges for imaging and dosimetry, particularly in standard clinical gamma cameras — requiring optimisation of imaging protocols or specialised equipment. SpringerLink+2PMC+2
Finally, compared with the decades of data accumulated for ¹⁷⁷Lu-based therapies, the body of clinical evidence for ¹⁶¹Tb remains relatively small. More clinical trials — including phase III studies — are needed to confirm long-term safety, optimal dosing, and effectiveness across diverse tumour types. ScienceDirect+2Open MedScience+2
What This Might Mean for Cancer Care
If ongoing clinical trials continue to show favourable safety and efficacy, ¹⁶¹Tb could reshape how we approach radionuclide therapy — especially with a shift toward treating minimal residual disease, early-stage micrometastasis, or single-cell clusters that are currently a major source of relapse.
Its “theranostic” nature — combining diagnostic imaging and therapy in one radionuclide — could streamline treatment planning, reduce patient burden, and help personalise therapy more precisely.
Furthermore, the versatility of ¹⁶¹Tb across different targeting moieties (e.g. PSMA ligands for prostate cancer; somatostatin analogues for neuroendocrine tumours; antibodies for lymphomas) creates the potential for broad application, beyond a single cancer type.
Conclusion
Targeted Radionuclide Therapy is growing increasingly sophisticated — and ¹⁶¹Tb may represent the next generation of radionuclides, combining proven beta and gamma emissions with the high-localised damage potential of conversion and Auger electrons.
While challenges remain — particularly in large-scale production and broader clinical validation — the early clinical and preclinical data are compelling. If these efforts bear out, ¹⁶¹Tb could become a powerful tool in the oncologist’s arsenal, especially when dealing with minimal residual disease or micrometastatic spread — key obstacles in achieving long-term remission.
In short: ¹⁶¹Tb doesn’t just promise a marginal improvement — it could redefine what we expect from radionuclide therapy.
BArcelona ‘25
Light Medical was delighted to attend EANM 2025 in Barcelona, where global leaders in nuclear medicine and molecular imaging gathered to explore the latest innovations in the field. The event provided a fantastic opportunity to connect with partners, customers, and researchers, while showcasing our trusted range of shielding and transport solutions — including Vial Shields, Lead Glass Shields, Tungsten Containers, Vi-Cad Transport Case, and Type A Packaging.
One of the most exciting themes at this year’s congress was the rapid advancement of alpha (Ac-225) and beta (Tb-161) therapies, which are transforming cancer treatment through highly targeted therapeutic isotopes. The Light Medical team was inspired by the groundbreaking research and discussions around how these therapies are driving demand for safer handling, enhanced shielding, and specialised transport systems — areas where our products play a vital supporting role.
We’re proud to contribute to this evolving landscape by developing equipment that supports the secure use, storage, and transport of therapeutic and diagnostic isotopes. Our conversations at EANM 2025 reinforced our commitment to innovation, safety, and customer collaboration.
A huge thank you to everyone who visited our stand and shared their insights. We look forward to building on these connections and continuing to support the future of nuclear medicine and radiopharmacy. See you at EANM 2026!
To find out more information baout our trusted partners, go to our home page here or the specific links below.
Isotopia - radiopharmaceuticals
Nuclear Shields - shielding
Raditech - shielding and isotope disposal
RadQual - calibration sources
ERS - calibrator sources
LITE DONE RIGHT
RadQual RadLite™ Flood Sources
An Overview
RadQual’s RadLite™ Flood Sources stand out as a streamlined, efficient solution for nuclear medicine quality control. They’re engineered to be 60% lighter and 60% thinner, all while maintaining the same reliable performance that professionals expect. What’s more? RadQual backs these sources with a 100% guarantee—a testament to the brand’s confidence in quality and consistency.
Size & Activity Options
RadLite™ sources come in a variety of form factors to suit different SPECT gamma camera configurations:
BM01L: 5 lb, 61.2 × 42.4 cm, 0.89 cm thick – activities: 5, 10, 15, or 20 mCi
BM02: 5 lb, 51.6 cm (dim unspecified), 1.78 cm thick – activities: 5, 10, or 15 mCi
BM04: 5 lb, 49.8 × 39.6 cm, 1.78 cm thick – activities: 10, 15, or 20 mCi
BM05: 2 lb, 28.5 × 28.5 cm, 1.78 cm thick – up to 20 mCi
BM07: 3 lb, 40.1 × 24.1 cm, 0.76 cm thick – 7.5, 10, or 15 mCi
BM55: 2 lb, 28.5 × 26.1 cm, 1.78 cm thick – 20 mCi
Tailored for Your Gamma Camera
RadQual provides comprehensive cross-reference charts, helping professionals select the right flood source for their camera. For instance:
A Philips Brightview camera (51.4 × 40.6 cm active area) aligns with a BM01L-10 source.
A GE Discovery NM 750b (square 22.9 × 22.9 cm area) fits well with BM05-20 for optimal performance.(radqual.com)
Why Go RadLite™?
Lightweight and slim design reduces physical strain during handling.
Each unit undergoes rigorous testing—100% of the UFOV (Useful Field of View) is measured to ensure no "hot" or "cold" spots.
Radionuclidic purity is exceptional, with Co-56/Co-58 impurities below 0.08%, ensuring accuracy and safety.
Every source is guaranteed to deliver at least 100% of its referenced activity, ensuring reliability in calibration procedures.
Complements in the Ecosystem
RadQual’s quality assurance doesn't stop there. They offer additional solutions to streamline workflow and enhance safety:
RadShield™: A lightweight alternative to heavy cases, offering effective radiation shielding (e.g., 0.04 mrem/h at 30 cm vs. 0.03 for a hard case using a 15 mCi source).(radqual.com)
RadScooter: A transport solution designed to safely move flood sources around without manual carrying. Ideal for BM01, BM02, and BM04 models.(radqual.com)
RadLite Shipper: A lightweight, recyclable Type A shipping package that lowers shipping and return costs.(radqual.com)
Wrap-Up
RadQual’s RadLite™ Flood Sources redefine quality control in nuclear medicine. Their lightweight, slim design, unmatched precision, and full guarantee make them an excellent choice for professionals demanding performance and efficiency. When paired with RadShield™, RadScooter, and the RadLite Shipper, they complete a workflow that’s safer, faster, and more cost-effective.
If you are interested please get in touch via our contact form or request a quote.
Links to our radioactive source manufacturer’s pages are RadQual and ERS.
BNMS Autumn Meeting 2025
Earlier this week, Light Medical was pleased to attend the Autumn BNMS Meeting at the historic Kia Oval in London.
The BNMS (British Nuclear Medicine Society) Autumn Meeting brought together clinicians, researchers, and industry partners from across the country to share the latest advances in nuclear medicine. The event provided an excellent opportunity for collaboration, knowledge exchange, and discussion on the future of the field.
Our team was delighted to meet with delegates, showcase our medical imaging and diagnostic solutions, and hear first-hand about the challenges and opportunities within nuclear medicine today. We greatly value the chance to connect with healthcare professionals and researchers who are driving innovation and improving patient care.
Light Medical is committed to supporting the nuclear medicine community, and we look forward to building on the conversations and connections made during the meeting.
We represented our partners RadQual, ERS, Nuclear Shields, Raditech, Elysia-Raytest and Isotopia
New DUAL protection syringe shields
Protect staff and improve precision with our new dual syringe shield, combining tungsten and Perspex for effective gamma and beta radiation protection.
Dual Syringe Shields
We’re excited to introduce the latest innovation in radiation safety: Dual Syringe Shields, specifically engineered for nuclear medicine professionals who demand both protection and precision.
Dual Protection – Gamma & Beta
Our syringe shields are constructed using a powerful combination of 4 mm tungsten and 5 mm Perspex, delivering dual-layer protection against both gamma and beta radiation. This makes them ideally suited for high-precision nuclear medicine procedures, where shielding from multiple radiation types is critical to both operator safety and procedural accuracy.
Safe Handling with Clear Visibility
A key feature of our Dual Syringe Shield is the narrow viewing window, manufactured with a thickness of 8.8 mm and a density of 5.2 g/cm³. This window provides enhanced radiation attenuation without compromising visibility—enabling clinicians to handle syringes safely and confidently during dosing and injection.
Stability with the Big-Screw System
To make clinical use even more efficient, each shield is equipped with a Big-Screw fixation system. This allows the syringe to be securely locked into place, preventing unwanted movement and ensuring accurate handling even during the most delicate procedures.
Designed for Nuclear Medicine Efficiency
Whether you’re working in a hospital radiopharmacy, PET center, or research facility, our Dual Syringe Shields are designed with practicality, protection, and performance in mind. The ergonomic design makes them easy to handle, while the robust construction ensures durability under frequent use.
Key Features at a Glance:
4 mm Tungsten + 5 mm Perspex for dual gamma/beta shielding
8.8 mm viewing window with 5.2 g/cm³ density for optimal visibility
Big-Screw locking system for syringe stability
Engineered for nuclear medicine safety and workflow efficiency
BNMS | Spring
Light Medical at the BNMS Spring Meeting 2025 – Driving Innovation in Nuclear Medicine
After a busy few months, the Light Medical team was proud to once again attend and exhibit at the BNMS Spring Meeting 2025 in Glasgow. The event brought together professionals from across nuclear medicine, radiopharmacy, medical physics, and radiology for three days of valuable insights, collaboration, and innovation.
A Standout Event
This year’s meeting was an excellent opportunity to reconnect with long-standing customers, suppliers, and partners, as well as introduce Light Medical to new faces in the field. With a packed programme of presentations and posters, there was plenty of engaging content covering key topics including Lu-177 therapies, Ga-68 PSMA, radiation protection, quality control, software, and the growing role of personalised radionuclide therapy.
What We Showcased
At our stand, we were proud to present a wide range of our latest technologies, all designed to support safe, accurate, and efficient workflows in nuclear medicine. These included:
Shielding Solutions – Syringe and vial shields for everyday protection
Sealed Sources – Co-57, Ge-68, Cs-137 for SPECT and PET calibration
TLC and HPLC Scanners – Ensuring precise and reliable QC
Shielded equipment, laminar flow and cabinets
Ga68 PSMA imaging cold kit
Collaboration at the Core
The event was also a fantastic opportunity to strengthen relationships with our partners, including Elysia-Raytest, Nuclear Shields, Epsilon (ERS), Isotopia, Raditech and RadQual. These collaborations are key to delivering high-quality, cutting-edge solutions to nuclear medicine departments across the UK and Ireland.
Looking Ahead
With nuclear medicine increasingly focused on personalised treatment and reducing radiation exposure, Light Medical is proud to be supporting this transition with innovative, safety-first products.
We're now looking forward to the BNMS Autumn Meeting at The Oval in London—another chance to engage with the community and help drive the future of nuclear medicine forward.
Thank you to everyone who stopped by our stand in Glasgow. See you in London!
Thank you and Merry Christmas
Merry Christmas!
As the festive season approaches, we at Light Medical would like to express our heartfelt gratitude to our valued customers and business partners (Nuclear Shields, RadQual, ERS sources, Elysia-Raytest, Von Gahlen, Isotopia and ec2 software solutions). Your support and commitment has been instrumental in our shared success this year.
Thank you for being an integral part of our journey. We look forward to further strengthening our partnership and achieving even greater milestones together in the years to come.
With warmest regards ,
Mark and Will
BNMS | AUTUMN
Strong presense at the BNMS and excitment for Belfast 2024
Light Medical, recently participated in the British Nuclear Medicine Meeting. Mark and Will attending the event held at 1 Wimpole Street the home of the Royal College of Medicine. At the event:
Cutting-Edge Technology: Light Medical showcased their latest shielding (syringe shields and vial shields), SPECT and PET sealed sources (Co-57, Ge-68, Cs-137), LIMS software, TLC and HPLC scanners, QC equipment. Setting new standards for accuracy and reducing radiation exposure, enhancing patient care.
Collaboration: They actively engaged with top companies and researchers to foster innovation and improve outcomes; ec² software solutions, Elysia-Raytest, Nuclear Shields, Epsilon (ERS), RadQual and Von Gahlen.
Key Takeaways:
Personalized Medicine: Nuclear medicine is moving towards personalized treatment plans and radionuclide therapy will play a huge part in that.
Reduced Radiation Exposure: Light Medical's innovative products prioritise user and patient safety with minimal radiation exposure.
Expanding Horizons: Ongoing work to improve market options for Nuclear Medicine, physics and radiopharamcy in the UK and Ireland.
In conclusion, a large delegate attendence at the British Nuclear Medicine Meeting reaffirms the commitment to driving nuclear medicine forward and improving patient care through cutting-edge technology and collaboration. The presence at the event signals strong support for the BNMS and the team are looking forward to Belfast 2024!
Radioactive Source Order deadlines for 2024
In partnership with Epsilon Radioactive Sources and RadQual Global Source we are planning to a do a bimonthly consolidated source order. This will include all the sources from both catalogues - Co57 flood sources, PET/CT sources (GE Healthcare, Siemens and Philips) pen point marker sources, siemens AQC sources spot marker sources and dose calibrator sources. This will also include the collection and return of old sources.
Order deadlines for 2024 deliveries
Friday 22nd December 2023
Thursday 29th February
Tuesday 30th April
Friday 28th June
Friday 30st August
Thursday 31st October
Friday 20th December (2025 delivery)
UK Radiopharmacy Group meeting 2023
Mark and Will attended the UK Radiopharmacy group meeting at Hinsley Hall, Leeds. It was an excellent meeting with talks ranging from the “Implementation of Annex 1” to “which PSMA is best?”. The consensus from our conversations with attendees was that the program was excellent, and the new venue was a refreshing change.
The team were there to represent our manufacturers in the exhibit space; Nuclear Shields, Von Gahlen, Elysia-Raytest, ec², RadQual, Epsilon and Isotopia. They were able to present Nuclear Shields range of demo syringe shields and vial shields on the first day.
The second day was a focussed LIMS software workshop day, with the team presenting the RMIS/NMIS software from ec² software solutions in the morning and taking part in a round table discussion in the afternoon.
Radioactive Source Delivery Schedule
In partnership with RadQual Global Source we are planning to a do a bimonthly consolidated source order. This will include all the sources from the RadQual range - Co57 flood sources, pen point marker sources, spot marker sources and dose calibrator sources. This will also include the collection and return of old sources.
Order deadlines for 2023 deliveries
23rd December 2022
28th February
28th April
30th June
31st August
31st October
22nd December (2024 delivery)
HOLA DE BARCELONA
EANM returned after several covid-19 impacted years. The team spent three days meeting with our customers and manufacturers planning for the year ahead. The strong scientific program was supported by a record turn out of delegates!
We look forward to attending EANM’23 next September in Vienna.
Bracco | RB82 Generator
ec² software solutions | Nuclear medicine and radiopharmacy management software
Elysia-Raytest | QC equipment
Epsilon Radioactive sources | PET and SPECT sources
Nuclear Shields | shielding, syringe and vial shields
Isotopia | PET radiopharmaceuticals
RadQual Global Sources | SPECT and PET sources
Von Gahlen | Hot Cell and Shielding
First conference back
After two covid years we were able to finally exhibit at the BNMS spring meeting. It was an excellent event that enabled us to catch up with customers and suppliers over the course of the 3-day schedule. Having not been able to attend any nuclear medicine or radiopharmacy conferences for such a long time, it was great to be able to finally introduce Light Medical to many new people from the nuclear medicine, radiopharmacy, medical physics and radiology profession. There were some excellent presentations and posters on subjects such as Lu177 therapies, radiation protection, software, quality control and radioisotope management.
We are looking forward to the autumn event in Swansea!
BNMS Spring Meeting May 2022
After two covid years we were able to finally exhibit at the BNMS spring meeting. It was an excellent event that enabled us to catch up with customers and suppliers over the course of the 3-day schedule. Having not been able to attend any nuclear medicine or radiopharmacy conferences for such a long time, it was great to be able to finally introduce Light Medical to many new people from the nuclear medicine, radiopharmacy, medical physics and radiology profession. There were some excellent presentations and posters on subjects such as Lu177 therapies, radiation protection, software, quality control and radioisotope management.
We are looking forward to the autumn event in Swansea!
Two days in Liege
The team spent two days this week in Liege as part of their training for the Elysia-Raytest portfolio. It was part of a two day service meeting that enables the service teams from across the world to get together and train on specific areas. The UK team were specifically learning about Gina X software, MiniGITA TLC Scanner, CR35 and AIDA software, GAIA synthesis unit and HPLC detectors and systems. It was great to meet all the other distributors and share stories over a Belgian beer. We look forward to another meeting with the team soon.
Elysia-Raytest Service Meeting | April 2022
The team spent two days this week in Liege as part of their training for the Elysia-Raytest portfolio. It was part of a two day service meeting that enables the service teams from across the world to get together and train on specific areas. The UK team were specifically learning about Gina X software, MiniGITA TLC Scanner, CR35 and AIDA software, GAIA synthesis unit and HPLC detectors and systems. It was great to meet all the other distributors and share stories over a Belgian beer. We look forward to another meeting with the team soon.